In the NALA study,24 neratinib combined with capecitabine demonstrated a greater PFS benefit than lapatinib plus capecitabine in patients with metastatic HER2-positive breast cancer previously treated with ≥2 HER2-targeted therapies. The gene discussed is ERBB2; the disease is breast carcinoma.